18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 10, 2009, Pages 1574-1582

  Lee, Jeong Won ^a   Kang, Keon Wook ^a   Park, Sung Hye ^a   Lee, Sang Mi ^a   Paeng, Jin Chul ^a   Chung, June Key ^a   Lee, Myung Chul ^a   Lee, Dong Soo ^a  

^a Seoul National University   (South Korea)

Author keywords

18F fluorodeoxyglucose (FDG); Meningioma; Positron emission tomography (PET); Prognosis; Recurrence

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BRAIN SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; HUMAN TISSUE; INTRACRANIAL TUMOR; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MITOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; BRAIN TUMOR; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SCINTISCANNING;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE;

EID: 70350548008     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1133-x     Document Type: Article

References (30)

1. C Marosi M Hassler K Roessler M Reni M Sant E Mazza, et al. 2008 Meningioma Crit Rev Oncol Hematol 67 153 171 10.1016/j.critrevonc.2008.01.010 18342535 10.1016/j.critrevonc.2008.01.010
2. BJ McCarthy FG Davis S Freels TS Surawicz DM Damek J Grutsch, et al. 1998 Factors associated with survival in patients with meningioma J Neurosurg 88 831 839 9576250 10.3171/jns.1998.88.5.0831 1:STN:280:DyaK1c3jsFOrsQ%3D%3D
3. H Maier D Ofner A Hittmair K Kitz H Budka 1992 Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance J Neurosurg 77 616 623 1527622 10.3171/jns.1992.77.4.0616 1:STN:280: DyaK38vgslKltg%3D%3D
4. DL Commins RD Atkinson ME Burnett 2007 Review of meningioma histopathology Neurosurg Focus 23 E3 10.3171/FOC-07/10/E3 17961040 10.3171/FOC-07/10/E3
5. LK Goyal JH Suh DS Mohan RA Prayson J Lee GH Barnett 2000 Local control and overall survival in atypical meningioma: a retrospective study Int J Radiat Oncol Biol Phys 46 57 61 10.1016/S0360-3016(99)00349-1 10656373 10.1016/S0360-3016(99)00349-1 1:STN:280:DC%2BD3c7itVWltA%3D%3D (Pubitemid 30021480)
6. JA Takahashi T Ueba N Hashimoto Y Nakashima N Katsuki 2004 The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas Surg Neurol 61 149 155 10.1016/S0090- 3019(03)00575-5 14751627 10.1016/S0090-3019(03)00575-5 (Pubitemid 38147494)
7. D Delbeke C Meyerowitz RL Lapidus RJ Maciunas MT Jennings PL Moots, et al. 1995 Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET Radiology 195 47 52 7892494 1:STN:280:DyaK2M7pvFGrsg%3D%3D
8. MV Padma S Said M Jacobs DR Hwang K Dunigan M Satter, et al. 2003 Prediction of pathology and survival by FDG PET in gliomas J Neurooncol 64 227 237 10.1023/A:1025665820001 14558598 10.1023/A:1025665820001 1:STN:280:DC%2BD3svotVWgsQ%3D%3D (Pubitemid 37203463)
9. R Hustinx M Pourdehnad B Kaschten A Alavi 2005 PET imaging for differentiating recurrent brain tumor from radiation necrosis Radiol Clin North Am 43 35 47 10.1016/j.rcl.2004.09.009 15693646 10.1016/j.rcl.2004.09.009 (Pubitemid 40326558)
10. G Di Chiro J Hatazawa DA Katz HV Rizzoli DJ De Michele 1987 Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study Radiology 164 521 526 3496626
11. U Cremerius R Bares J Weis O Sabri M Mull JM Schröder, et al. 1997 Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET J Nucl Med 38 26 30 8998144 1:STN:280:DyaK2s7lt1aisA%3D%3D
12. B Lippitz U Cremerius L Mayfrank H Bertalanffy R Raoofi J Weis, et al. 1996 PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate Acta Neurochir Suppl 65 108 111 8738510 1:STN:280:DyaK28zjs1ehsA%3D%3D
13. YS Park BC Jeon HS Oh SM Lee BK Chun HK Chang 2006 FDG PET/CT assessment of the biological behavior of meningiomas J Korean Neurosurg Soc 40 428 433 1:CAS:528:DC%2BD2sXhtF2ks7c%3D
14. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A. Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, et al., editors. World Health Organization classification of tumours of the central nervous system. 4th ed. Lyon: IARC; 2007. p. 164-72.
15. EM Rohren TG Turkington RE Coleman 2004 Clinical applications of PET in oncology Radiology 231 305 332 10.1148/radiol.2312021185 15044750 10.1148/radiol.2312021185 (Pubitemid 38552885)
16. T Iuchi Y Iwasate H Namba K Osato N Saeki A Yamaura, et al. 1999 Glucose and methionine uptake and proliferative activity in meningiomas Neurol Res 21 640 644 10555183 1:CAS:528:DyaK1MXnsFSgu7o%3D
17. F Bénard J Romsa R Hustinx 2003 Imaging gliomas with positron emission tomography and single-photon emission computed tomography Semin Nucl Med 33 148 162 10.1053/snuc.2003.127304 12756647 10.1053/snuc.2003.127304 (Pubitemid 36577057)
18. T Singhal TK Narayanan V Jain J Mukherjee J Mantil 2008 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas Mol Imaging Biol 10 1 18 10.1007/s11307-007-0115-2 17957408 10.1007/s11307-007-0115- 2
19. WA Weber HJ Wester AL Grosu M Herz B Dzewas HJ Feldmann, et al. 2000 O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study Eur J Nucl Med 27 542 549 10.1007/s002590050541 10853810 10.1007/s002590050541 1:CAS:528: DC%2BD3cXis1Oqtrw%3D
20. JK Chung YK Kim SK Kim YJ Lee S Paek JS Yeo, et al. 2002 Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET Eur J Nucl Med Mol Imaging 29 176 182 10.1007/s00259-001-0690-4 11926379 10.1007/s00259-001-0690-4 1:CAS:528:DC%2BD38XnvFSmtg%3D%3D
21. O Gudjonsson E Blomquist A Lilja H Ericson M Bergström G Nyberg 2000 Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-L-methionine PET Eur J Nucl Med 27 1793 1799 10.1007/s002590000335 11189942 10.1007/s002590000335 1:CAS:528: DC%2BD3cXosVOlsrs%3D
22. AL Grosu WA Weber ST Astner M Adam BJ Krause M Schwaiger, et al. 2006 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy Int J Radiat Oncol Biol Phys 66 339 344 10.1016/j.ijrobp. 2006.02.047 16765533 1:CAS:528:DC%2BD28Xptlyqs7k%3D
23. KW Ko DH Nam DS Kong JI Lee K Park JH Kim 2007 Relationship between malignant subtypes of meningioma and clinical outcome J Clin Neurosci 14 747 753 10.1016/j.jocn.2006.05.005 17499508 10.1016/j.jocn.2006.05.005 (Pubitemid 46907600)
24. DK Böker H Meurer F Gullotta 1985 Recurring intracranial meningiomas. Evaluation of some factors predisposing for tumor recurrence J Neurosurg Sci 29 11 17 4067631
25. R Sasaki R Komaki H Macapinlac J Erasmus P Allen K Forster, et al. 2005 [18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer J Clin Oncol 23 1136 1143 10.1200/JCO.2005.06.129 15718309 10.1200/JCO.2005.06.129 1:CAS:528:DC%2BD2MXitl2gtbc%3D (Pubitemid 46202269)
26. SG Swisher M Maish JJ Erasmus AM Correa JA Ajani R Bresalier, et al. 2004 Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer Ann Thorac Surg 78 1152 1160 10.1016/j.athoracsur.2004.04.046 15464463 10.1016/j.athoracsur.2004.04.046 (Pubitemid 39303827)
27. B Nakata S Nishimura T Ishikawa M Ohira H Nishino J Kawabe, et al. 2001 Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer Int J Oncol 19 53 58 11408922 1:STN:280:DC%2BD3MzksFCitw%3D%3D
28. JB Alavi A Alavi J Chawluk M Kushner J Powe W Hickey, et al. 1988 Positron emission tomography in patients with glioma. A predictor of prognosis Cancer 62 1074 1078 10.1002/1097-0142(19880915)62:6<1074::AID- CNCR2820620609>3.0.CO;2-H 3261622 10.1002/1097-0142(19880915)62:6<1074:: AID-CNCR2820620609>3.0.CO;2-H 1:STN:280:DyaL1czhtVOmsQ%3D%3D (Pubitemid 18206326)
29. K Mineura T Sasajima M Kowada T Ogawa J Hatazawa F Shishido, et al. 1994 Perfusion and metabolism in predicting the survival of patients with cerebral gliomas Cancer 73 2386 2394 10.1002/1097-0142(19940501)73:9<2386::AID- CNCR2820730923>3.0.CO;2-W 8168042 10.1002/1097-0142(19940501)73:9<2386:: AID-CNCR2820730923>3.0.CO;2-W 1:STN:280:DyaK2c3itFGgug%3D%3D
30. J Jääskeläinen M Haltia A Servo 1986 Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome Surg Neurol 25 233 242 10.1016/0090-3019(86)90233-8 3945904 10.1016/0090-3019(86) 90233-8 (Pubitemid 16175898)